Epitalon, explained.
Epithalon. Research, safety questions, and treatment context.
The form
Preparation matters
The routine
No personal schedule is set by this guide.
The evidence
See the evidence and source notes below.
Research, approval and availability are separate questions.
On this page
A linked source is not a clinical endorsement. How we handle review and corrections.
- Legal status
- Backed by FDA advisers, awaiting final rule
FDA advisers voted 7 to 4 on July 24, 2026 to allow compounding, after reviewing it for insomnia.
- At Goodmorrow
- Waitlist open
What it is
Epitalon is a synthetic version of a peptide extract from the pineal gland, the part of the brain that manages melatonin and sleep timing.
What the evidence shows
Most of the research comes from one group of Russian scientists, and the longevity claims rest heavily on cell studies of telomeres. The FDA reviewed it for insomnia.
How Goodmorrow handles it
We'll consider it for sleep once it's lawful. On longevity, the honest answer is that nobody has shown it extends life in people.
Stacks that include it
- Longevity stack: mots-c, epitalon and nad+
Follow updates about Epitalon
Join the update list. This does not reserve a treatment or mean that future availability is assured.
Questions people ask
Does epitalon lengthen telomeres?
It did in cell studies. Whether that happens in people, and whether it would matter if it did, hasn't been shown.
Sources
- Secondary sourceFDA advisory panel narrowly rejects compounding of one peptide, backs two others STAT, July 24, 2026
- FDA documentJuly 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee U.S. Food and Drug Administration, July 2026
- Secondary sourceBulk-list bound? PCAC backs majority of peptides in two-day public meeting McDermott Will & Schulte, July 28, 2026
Good days ahead.
Join the opening list for appointment updates.